Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase I/Ib Study of Its Novel PARP Inhibitor (RP12146) in Patients With Advanced Solid Tumors
Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focused biopharmaceutical company, announced today that it has commenced dosing in a multi-center, phase I/Ib trial to evaluate its novel poly (ADP-ribose) polymerase (PARP) inhibitor (RP12146) in patients with advanced solid tumors. This two-part multi-center phase I/Ib study is being conducted in Europe and has been designed to initially determine safety, tolerability, maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of RP12146 and to subsequently assess its anti-tumor activity in expansion cohorts with HRR mutation-enriched ES-SCLC, ovarian and breast cancer patients.
Rhizen indicated that RP12146 has shown preclinical activity and efficacy comparable to the approved PARP inhibitor Olaparib, and shows improved safety as seen in the preclinical IND-enabling toxicology studies; an advantage that Rhizen hopes will translate in the clinical studies. Rhizen also announced that its PARP program is part of a larger DNA Damage Response (DDR) platform effort, which includes a preclinical-stage polymerase theta (Polθ) inhibitor program. Rhizen expects the platform to enable novel proprietary combinations of its PARP and Polθ assets given the mechanistic synergy and opportunity across PARP resistant/refractory settings.
“PARP inhibitors are a great success story in the DNA damage response area, but they are not without safety concerns that have limited realization of their full potential. Although our novel PARP inhibitor is competing in a crowded space, we expect its superior preclinical safety to translate into the clinic which will differentiate our program and allow us to extend its application beyond the current landscape of approved indications and combinations”, said Swaroop Vakkalanka, Founder & CEO of Rhizen Pharma. Swaroop also added that “Our PARP program is foundational for our DDR platform efforts and will be the backbone for several novel proprietary combinations that we hope to bring into development going forward.”
About Rhizen Pharmaceuticals AG.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology & inflammation therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.
Rhizen has proven expertise in the PI3K modulator space with the discovery of our first PI3Kδ & CK1ε asset Umbralisib, that has been successfully developed & commercialized in MZL & FL by our licensing partner TG Therapeutics (TGTX) in USA. Beyond this, Rhizen has a deep oncology & inflammation pipeline spanning discovery to phase II clinical development stages.
Rhizen is headquartered in Basel, Switzerland. For additional information, please visit https://www.rhizen.com/
Safe Harbor
This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005515/en/
Contact information
Rhizen Pharmaceuticals AG - Contact:
Samyukta Bhagwati
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals AG.
Telephone: +41 32 580 0113
Email: corpcomm@rhizen.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gogo Galileo HDX Coming to Cessna Citation Jet Models1.7.2025 18:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Gogo Galileo HDX will be available for aftermarket installation on Cessna Citation jets after Federal Aviation Administration (FAA) Supplemental Type Certification (STC) expected in late 2025. The global Low Earth Orbit (LEO) solution allows customers to enjoy one of the best possible in-flight connectivity and aviation experiences, no matter where their journey takes them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701750049/en/ Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced Gogo Galileo HDX will be available for aftermarket installation on Cessna Citation jets after Federal Aviation Administration (FAA) Supplemental Type Certification (STC) expected in late 2025. (Photo: Textron Aviation) By offering Gogo Galileo HDX as an aftermarket upgrade, the Textron Aviation support team is ensuring customers benefit from a g
Amos Food Wins Award at ESG Conference Held in Stuttgart1.7.2025 17:44:00 EEST | Press release
The 2nd Sino-European Corporate ESG Best Practice Conference, hosted by the Chinese Consulate General in Frankfurt, took place on June 26, 2025, in Stuttgart, Germany. Several companies were honored with Best Practice awards across six categories, with Amos Food Group receiving the Best Practice Award for Social Responsibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701126324/en/ Amos Ma, Chairman of Amos Food Group, delivered a speech at the conference. With the theme “Together We Are Strong – For a More Innovative, Healthy, Intelligent, and Sustainable Future,” the conference was hosted by the Chinese Consulate General in Frankfurt in collaboration with German institutions including GIZ (German Society for International Cooperation), the Baden-Württemberg IHK (Chamber of Commerce and Industry), KPMG Germany, as well as Chinese partners including the China-Europe Business Council. According to the jury composed o
Chinese and European Enterprises Gather in Stuttgart to Discuss ESG Cooperation1.7.2025 17:19:00 EEST | Press release
The 2nd Sino-European Corporate ESG Best Practice Conference, hosted by the Chinese Consulate General in Frankfurt, was held on June 26th, 2025 in Stuttgart, Germany. Representatives from various sectors of China and Europe attended the event and agreed that ESG development is becoming a new focal point for exchange and cooperation between Chinese and European enterprises. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701883046/en/ German participant tries the food of Beiwei 47 at the conference. Klaus Paal, President of the Stuttgart Chamber of Commerce and Industry, also emphasized that in today’s era of global transformation, ESG is a highly important topic and a key platform for enterprises from different countries to enhance communication and cooperation. Torsten Giehler, Director of the Economic and Social Development Department at GIZ (German Agency for International Cooperation), pointed out that ESG is no longer
Dar Appointed as Independent Engineer to Facilitate the Modernization and Expansion of Paris-Beauvais Airport1.7.2025 17:19:00 EEST | Press release
Dar, a Sidara company, has been engaged as an Independent Engineer to support a five-year investment program, designed to modernize and expand the airport infrastructure of the Paris-Beauvais Airport, in France, serving five million passengers a year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250701051744/en/ As the Independent Engineer, Dar will support the modernization and expansion of Paris-Beauvais Airport (Photo: AETOSWire) Launched by SPV Bellova and to be carried out by a design-build consortium (CC) which comprises Bouygues Bâtiment Grand Ouest, Bouygues Bâtiment International, Egis Avia, Egis Bâtiment, and Ameller Dubois, the modernization project includes airside, landside, parking, and building works as well as equipment installation. As an Independent Engineer and through its local office, Dar France, the company will audit the design stages, monitor construction and project acceptance, and supervise and va
Andersen Consulting Collaborates with Mercurial Minds to Enhance Digital Transformation Capabilities1.7.2025 16:30:00 EEST | Press release
Andersen Consulting expands its capabilities in delivering technology-driven solutions with the addition of collaborating firm Mercurial Minds (M.M.), a digital transformation, AI, and IT consulting firm based in Pakistan. Founded in 2013, M.M. provides a suite of services designed to help organizations evolve and scale, including their digital transformation strategy, AI services, IT consulting, and the development of robust mobile and web user experiences. The firm delivers end-to-end solutions—defining data-driven roadmaps, engineering intelligent automation, and delivering secure mobile and web experiences that scale—tailored for businesses seeking to enhance connectivity and unlock real-time insights. M.M. serves a diverse range of industries, with a focus on the financial, telecommunications, and other data-intensive sectors. “This collaboration is a catalyst,” said Nabeel Saiyer, CEO of M.M. “Our goal is to shape sentient systems that continually learn and adapt. Collaborating w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom